Myasthenia Gravis: FcRn Inhibitors and Complement-Directed Therapies
Pathophysiology-Based Treatment Selection
Myasthenia gravis (MG) is driven by pathogenic autoantibodies at the neuromuscular junction. Anti-acetylcholine receptor (AChR) antibodies are present in 85% of generalized MG cases, while anti-muscle-specific kinase (MuSK) antibodies account for 5-8%. The remaining seronegative cases may harbor low-affinity AChR antibodies detectable by cell-based assays. This antibody subtyping is critical for treatment selection: AChR-positive MG responds to complement inhibition (since AChR antibodies activate complement), while MuSK-MG (mediated by IgG4, which does not activate complement) responds to FcRn inhibitors and B-cell depletion but not complement-directed therapy.
FcRn Inhibitors: Efgartigimod and Rozanolixizumab
Neonatal Fc receptor (FcRn) inhibitors accelerate IgG catabolism, reducing pathogenic antibody levels by 70-80% within 1-2 weeks. Efgartigimod (Vyvgart) was FDA-approved in 2021 for generalized AChR-positive MG based on the ADAPT trial: 67.7% of treated patients achieved clinically meaningful improvement on the MG-ADL scale (4-point or more reduction) versus 29.7% for placebo (p<0.0001). The subcutaneous formulation with hyaluronidase (Vyvgart Hytrulo) was approved in 2023 for home administration. Rozanolixizumab received FDA approval in 2023 based on the MycarinG trial, showing MG-ADL improvement of -3.37 points versus -0.78 for placebo at day 43 (p<0.0001). Both agents produce cyclical IgG reduction, and optimal re-treatment timing is guided by clinical worsening.
Complement Inhibitors: Eculizumab and Ravulizumab
Terminal complement inhibition with the anti-C5 monoclonal antibody eculizumab (Soliris) was approved for refractory generalized AChR-positive MG based on the REGAIN trial, which showed a clinically meaningful MG-ADL response in 56% versus 31% for placebo. Ravulizumab (Ultomiris), a long-acting anti-C5 antibody requiring infusion only every 8 weeks versus every 2 weeks for eculizumab, demonstrated noninferiority in the CHAMPION-MG trial with MG-ADL improvement of -3.1 points versus -1.4 for placebo (p<0.0001). Zilucoplan, a subcutaneous peptide C5 inhibitor, was approved in 2023 (RAISE trial: MG-ADL -4.39 versus -2.30 for placebo, p<0.0001), offering the first self-injectable complement inhibitor.
Sponsored
Integrating Novel Therapies with Standard Treatment
Standard MG therapy begins with pyridostigmine for symptomatic relief (starting at 60 mg TID, titrated to 120 mg TID maximum). Immunosuppression with prednisone (0.5-1 mg/kg/day, tapered to the minimum effective dose) remains the most widely used disease-modifying therapy, often combined with steroid-sparing agents (azathioprine 2-3 mg/kg/day, mycophenolate 1-1.5 g BID, or rituximab 375 mg/m² for MuSK-MG). Novel targeted therapies (FcRn and complement inhibitors) are currently positioned for patients with refractory generalized disease or those requiring rapid treatment initiation. However, accumulating real-world data suggest earlier use may reduce cumulative steroid exposure and associated morbidity.
Thymectomy and Crisis Management
The MGTX trial definitively established the benefit of thymectomy in non-thymomatous AChR-positive generalized MG: at 5 years, thymectomy plus prednisone achieved greater improvement in QMG score (-19.2 versus -14.3, p=0.001) with lower prednisone requirements (24 mg versus 48 mg alternate-day equivalent). Thymectomy is recommended for all patients with thymoma and for AChR-positive generalized MG patients aged 18-65. Myasthenic crisis (respiratory failure requiring intubation) occurs in 15-20% of MG patients and is managed with IVIG (2 g/kg over 2-5 days) or plasma exchange (5 sessions over 10 days), with comparable efficacy (time to improvement 4-5 days). FcRn inhibitors are being studied as bridge therapy in crisis prevention.
Sponsored
Want to try Ailva?
Ailva is a clinical intelligence platform that delivers evidence-based answers with verified citations and cross-system reasoning. Free for all NPI holders.